FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder
Portfolio Pulse from Vandana Singh
The FDA has approved Regeneron Pharmaceuticals' drug, Veopoz, for the treatment of CHAPLE disease in adults and children over one year old. Veopoz is the first and only treatment specifically for CHAPLE, an ultra-rare and life-threatening hereditary immune disease. The drug will be sold in the U.S. at a list price of $34,615.38 per single-use vial. Following the news, REGN shares rose by 1.45%.
August 21, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's shares rose by 1.45% following the FDA approval of its drug, Veopoz. The drug is the first and only treatment for CHAPLE disease and will be sold at a list price of $34,615.38 per single-use vial.
The FDA approval of Veopoz, the first and only treatment for CHAPLE disease, is a significant milestone for Regeneron. This approval could potentially open up a new revenue stream for the company, given the high list price of the drug. The news has already positively impacted the company's stock price, which rose by 1.45%.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100